ABIOMED (ABMD) Receiving Somewhat Positive Media Coverage, Analysis Shows

News coverage about ABIOMED (NASDAQ:ABMD) has trended somewhat positive this week, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than 6,000 blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. ABIOMED earned a news sentiment score of 1.67 on their scale. InfoTrie also gave media stories about the medical equipment provider an news buzz score of 3 out of 10, indicating that recent media coverage is unlikely to have an impact on the company’s share price in the near term.

These are some of the media stories that may have impacted ABIOMED’s analysis:

ABMD has been the subject of several analyst reports. Morgan Stanley upgraded ABIOMED from an “equal” rating to a “weight” rating and upped their target price for the company from $396.00 to $496.00 in a report on Wednesday. Zacks Investment Research cut ABIOMED from a “buy” rating to a “hold” rating in a report on Tuesday, July 31st. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a report on Wednesday, September 5th. BTIG Research upgraded ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 target price for the company in a report on Friday, November 2nd. Finally, ValuEngine cut ABIOMED from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 18th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $402.78.

Shares of NASDAQ:ABMD opened at $412.10 on Thursday. The firm has a market capitalization of $17.50 billion, a price-to-earnings ratio of 168.20, a P/E/G ratio of 3.18 and a beta of 0.35. ABIOMED has a 52-week low of $186.72 and a 52-week high of $459.75.

ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, November 1st. The medical equipment provider reported $1.09 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.36. ABIOMED had a return on equity of 20.09% and a net margin of 27.60%. The business had revenue of $181.78 million for the quarter, compared to analyst estimates of $175.41 million. During the same quarter in the prior year, the company posted $0.54 EPS. The company’s quarterly revenue was up 36.9% on a year-over-year basis. As a group, equities research analysts anticipate that ABIOMED will post 3.57 earnings per share for the current year.

In other news, VP Michael G. Howley sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $432.50, for a total value of $4,325,000.00. Following the transaction, the vice president now owns 48,954 shares of the company’s stock, valued at approximately $21,172,605. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Andrew J. Greenfield sold 4,440 shares of the company’s stock in a transaction on Wednesday, August 29th. The shares were sold at an average price of $395.00, for a total value of $1,753,800.00. The disclosure for this sale can be found here. Corporate insiders own 3.50% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was first posted by WKRB News and is the property of of WKRB News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.wkrb13.com/2018/11/08/abiomed-abmd-receiving-somewhat-positive-media-coverage-analysis-shows.html.


ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Read More: What is Cost of Debt?

Insider Buying and Selling by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply